Preliminary analysis of the expression of selected proangiogenic and antioxidant genes and microRNAs in patients with non-muscle-invasive bladder cancer

Journal of Clinical Medicine

Volumn 5, Issue 3, 2016, Pages

  Kozakowska, Magdalena ^a   Dobrowolska Glazar, Barbara ^b   Okoń, Krzysztof ^b   Józkowicz, Alicja ^a   Dobrowolski, Zygmunt ^b,c   Dulak, Józef ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c UNIVERSITY OF RZESZÓW   (Poland)

Author keywords

Angiogenesis; Bladder cancer; Heme oxygenase 1; Hypoxia inducible factor; MiR 155; MiR 200c; Nrf2; Urothelial cancer; VEGF

Indexed keywords

GAMMA INTERFERON; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 8; MICRORNA; MICRORNA 155; MICRORNA 200C; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR NRF2; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANTIOXIDANT GENE; ARTICLE; CELL PROTECTION; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NON MUSCLE INVASIVE BLADDER CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA ISOLATION; TUMOR BIOPSY; VERY ELDERLY;

EID: 85019155280     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5030029     Document Type: Article

References (78)

1. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012. Int. J. Cancer 2015, 136, E359-E386. [CrossRef] [PubMed]
2. Wein, A.J. Cambell-Walsh Urology, 10th ed.; Elsevier Saunders: Philadelphia, PA, USA, 2012.
3. Sawicka, E.; Lisowska, A.; Kowal, P.; Dlugosz, A. The role of oxidative stress in bladder cancer. Postepy Hig. Med. Dosw. 2015, 69, 744-752. [CrossRef] [PubMed]
4. Florczyk, U.; Loboda, A.; Stachurska, A.; Jozkowicz, A.; Dulak, J. Role of Nrf2 transcription factor in cellular response to oxidative stress. Postepy Biochem. 2010, 56, 147-155. [PubMed]
5. Iida, K.; Itoh, K.; Kumagai, Y.; Oyasu, R.; Hattori, K.; Kawai, K.; Shimazui, T.; Akaza, H.; Yamamoto, M. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 2004, 64, 6424-6431. [CrossRef] [PubMed]
6. Iida, K.; Itoh, K.; Maher, J.M.; Kumagai, Y.; Oyasu, R.; Mori, Y.; Shimazui, T.; Akaza, H.; Yamamoto, M. Nrf2 and p53 cooperatively protect against bbn-induced urinary bladder carcinogenesis. Carcinogenesis 2007, 28, 2398-2403. [CrossRef] [PubMed]
7. Paonessa, J.D.; Ding, Y.; Randall, K.L.; Munday, R.; Argoti, D.; Vouros, P.; Zhang, Y. Identification of an unintended consequence of Nrf2-directed cytoprotection against a key tobacco carcinogen plus a counteracting chemopreventive intervention. Cancer Res. 2011, 71, 3904-3911. [CrossRef] [PubMed]
8. Paonessa, J.D.; Munday, C.M.; Mhawech-Fauceglia, P.; Munday, R.; Zhang, Y. 5,6-dihydrocyclopenta[c][1,2]-dithiole-3(4H)-thione is a promising cancer chemopreventive agent in the urinary bladder. Chem. Biol. Interact. 2009, 180, 119-126. [CrossRef] [PubMed]
9. Hayden, A.; Douglas, J.; Sommerlad, M.; Andrews, L.; Gould, K.; Hussain, S.; Thomas, G.J.; Packham, G.; Crabb, S.J. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urol. Oncol. 2014, 32, 806-814. [CrossRef] [PubMed]
10. Kocanova, S.; Buytaert, E.; Matroule, J.Y.; Piette, J.; Golab, J.; de Witte, P.; Agostinis, P. Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. Apoptosis 2007, 12, 731-741. [CrossRef] [PubMed]
11. Loboda, A.; Jozkowicz, A.; Dulak, J. HIF-1 versus HIF-2—Is one more important than the other? Vasc. Pharmacol. 2012, 56, 245-251. [CrossRef] [PubMed]
12. Loboda, A.; Jozkowicz, A.; Dulak, J. HIF-1 and HIF-2 transcription factors-similar but not identical. Mol. Cells 2010, 29, 435-442. [CrossRef] [PubMed]
13. Theodoropoulos, V.E.; Lazaris, A.; Sofras, F.; Gerzelis, I.; Tsoukala, V.; Ghikonti, I.; Manikas, K.; Kastriotis, I. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur. Urol. 2004, 46, 200-208. [CrossRef] [PubMed]
14. Ioachim, E.; Michael, M.; Salmas, M.; Michael, M.M.; Stavropoulos, N.E.; Malamou-Mitsi, V. Hypoxia-inducible factors HIF-1α and HIF-2α expression in bladder cancer and their associations with other angiogenesis-related proteins. Urol. Int. 2006, 77, 255-263. [CrossRef] [PubMed]
15. Chai, C.Y.; Chen, W.T.; Hung, W.C.; Kang, W.Y.; Huang, Y.C.; Su, Y.C.; Yang, C.H. Hypoxia-inducible factor-1 alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J. Clin. Pathol. 2008, 61, 658-664. [CrossRef] [PubMed]
16. Deniz, H.; Karakok, M.; Yagci, F.; Guldur, M.E. Evaluation of relationship between HIF-1α immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas. Int. Urol. Nephrol. 2010, 42, 103-107. [CrossRef] [PubMed]
17. Jones, A.; Fujiyama, C.; Blanche, C.; Moore, J.W.; Fuggle, S.; Cranston, D.; Bicknell, R.; Harris, A.L. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin. Cancer Res. 2001, 7, 1263-1272. [PubMed]
18. Inoue, K.; Slaton, J.W.; Karashima, T.; Yoshikawa, C.; Shuin, T.; Sweeney, P.; Millikan, R.; Dinney, C.P. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin. Cancer Res. 2000, 6, 4866-4873. [PubMed]
19. Kopparapu, P.K.; Boorjian, S.A.; Robinson, B.D.; Downes, M.; Gudas, L.J.; Mongan, N.P.; Persson, J.L. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013, 33, 2381-2390. [PubMed]
20. Nakanishi, R.; Oka, N.; Nakatsuji, H.; Koizumi, T.; Sakaki, M.; Takahashi, M.; Fukumori, T.; Kanayama, H.O. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol. Int. 2009, 83, 98-106. [CrossRef] [PubMed]
21. Mazzola, C.R.; Chin, J. Targeting the VEGF pathway in metastatic bladder cancer. Expert Opin. Investig. Drugs 2015, 24, 913-927. [CrossRef] [PubMed]
22. Loboda, A.; Jazwa, A.; Grochot-Przeczek, A.; Rutkowski, A.J.; Cisowski, J.; Agarwal, A.; Jozkowicz, A.; Dulak, J. Heme oxygenase-1 and the vascular bed: From molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 2008, 10, 1767-1812. [CrossRef] [PubMed]
23. Was, H.; Dulak, J.; Jozkowicz, A. Heme oxygenase-1 in tumor biology and therapy. Curr. Drug Targets 2010, 11, 1551-1570. [CrossRef] [PubMed]
24. Miyake, M.; Fujimoto, K.; Anai, S.; Ohnishi, S.; Kuwada, M.; Nakai, Y.; Inoue, T.; Matsumura, Y.; Tomioka, A.; Ikeda, T.; et al. Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol. Rep. 2011, 25, 653-660. [CrossRef] [PubMed]
25. Miyake, M.; Fujimoto, K.; Anai, S.; Ohnishi, S.; Nakai, Y.; Inoue, T.; Matsumura, Y.; Tomioka, A.; Ikeda, T.; Okajima, E.; et al. Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cells. Anticancer Res. 2010, 30, 2145-2152. [PubMed]
26. Miyake, M.; Ishii, M.; Kawashima, K.; Kodama, T.; Sugano, K.; Fujimoto, K.; Hirao, Y. Sirna-mediated knockdown of the heme synthesis and degradation pathways: Modulation of treatment effect of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines. Photochem. Photobiol. 2009, 85, 1020-1027. [CrossRef] [PubMed]
27. Miyake, M.; Fujimoto, K.; Anai, S.; Ohnishi, S.; Nakai, Y.; Inoue, T.; Matsumura, Y.; Tomioka, A.; Ikeda, T.; Tanaka, N.; et al. Clinical significance of heme oxygenase-1 expression in non-muscle-invasive bladder cancer. Urol. Int. 2010, 85, 355-363. [CrossRef] [PubMed]
28. Miyata, Y.; Kanda, S.; Mitsunari, K.; Asai, A.; Sakai, H. Heme oxygenase-1 expression is associated with tumor aggressiveness and outcomes in patients with bladder cancer: A correlation with smoking intensity. Transl. Res. J. Lab. Clin. Med. 2014, 164, 468-476. [CrossRef] [PubMed]
29. Kim, J.H.; Park, J. Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer. Hum. Pathol. 2014, 45, 1830-1838. [CrossRef] [PubMed]
30. Kozakowska, M.; Ciesla, M.; Stefanska, A.; Skrzypek, K.; Was, H.; Jazwa, A.; Grochot-Przeczek, A.; Kotlinowski, J.; Szymula, A.; Bartelik, A.; et al. Heme oxygenase-1 inhibits myoblast differentiation by targeting myomirs. Antioxid. Redox Signal. 2012, 16, 113-127. [CrossRef] [PubMed]
31. Skrzypek, K.; Tertil, M.; Golda, S.; Ciesla, M.; Weglarczyk, K.; Collet, G.; Guichard, A.; Kozakowska, M.; Boczkowski, J.; Was, H.; et al. Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. Antioxid. Redox Signal. 2013, 19, 644-660. [CrossRef] [PubMed]
32. Tertil, M.; Golda, S.; Skrzypek, K.; Florczyk, U.; Weglarczyk, K.; Kotlinowski, J.; Maleszewska, M.; Czauderna, S.; Pichon, C.; Kieda, C.; et al. Nrf2-heme oxygenase-1 axis in mucoepidermoid carcinoma of the lung: Antitumoral effects associated with down-regulation of matrix metalloproteinases. Free Radic. Biol. Med. 2015, 89, 147-157. [CrossRef] [PubMed]
33. Wang, G.; Chan, E.S.; Kwan, B.C.; Li, P.K.; Yip, S.K.; Szeto, C.C.; Ng, C.F. Expression of microRNAs in the urine of patients with bladder cancer. Clin. Genitourin. Cancer 2012, 10, 106-113. [CrossRef] [PubMed]
34. Schaefer, A.; Stephan, C.; Busch, J.; Yousef, G.M.; Jung, K. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat. Rev. 2010, 7, 286-297. [CrossRef] [PubMed]
35. Adam, L.; Zhong, M.; Choi, W.; Qi, W.; Nicoloso, M.; Arora, A.; Calin, G.; Wang, H.; Siefker-Radtke, A.; McConkey, D.; et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15, 5060-5072. [CrossRef] [PubMed]
36. Zhou, H.; Tang, K.; Xiao, H.; Zeng, J.; Guan, W.; Guo, X.; Xu, H.; Ye, Z. A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J. Exp. Clin. Cancer Res. CR 2015, 34, 53. [CrossRef] [PubMed]
37. Gravgaard, K.H.; Lyng, M.B.; Laenkholm, A.V.; Sokilde, R.; Nielsen, B.S.; Litman, T.; Ditzel, H.J. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res. Treat. 2012, 134, 207-217. [CrossRef] [PubMed]
38. Panda, H.; Pelakh, L.; Chuang, T.D.; Luo, X.; Bukulmez, O.; Chegini, N. Endometrial miR-200c is altered during transformation into cancerous states and targets the expression of ZEBs, VEGFA, FLT1, IKKβ, KLF9, and FBLN5. Reprod. Sci. 2012, 19, 786-796. [CrossRef] [PubMed]
39. Han, Y.; Chen, J.; Zhao, X.; Liang, C.; Wang, Y.; Sun, L.; Jiang, Z.; Zhang, Z.; Yang, R.; Chen, J.; et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS ONE 2011, 6, e18286. [CrossRef] [PubMed]
40. Li, X.; Chen, J.; Hu, X.; Huang, Y.; Li, Z.; Zhou, L.; Tian, Z.; Ma, H.; Wu, Z.; Chen, M.; et al. Comparative mrna and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events. PLoS ONE 2011, 6, e22570. [CrossRef] [PubMed]
41. Mahdavinezhad, A.; Mousavi-Bahar, S.H.; Poorolajal, J.; Yadegarazari, R.; Jafari, M.; Shabab, N.; Saidijam, M. Evaluation of miR-141, miR-200c, miR-30b expression and clinicopathological features of bladder cancer. Int. J. Mol. Cell. Med. 2015, 4, 32-39. [PubMed]
42. Wszolek, M.F.; Rieger-Christ, K.M.; Kenney, P.A.; Gould, J.J.; Silva Neto, B.; Lavoie, A.K.; Logvinenko, T.; Libertino, J.A.; Summerhayes, I.C. A microRNA expression profile defining the invasive bladder tumor phenotype. Urol. Oncol. 2011, 29, 794-801. [CrossRef] [PubMed]
43. Wiklund, E.D.; Bramsen, J.B.; Hulf, T.; Dyrskjot, L.; Ramanathan, R.; Hansen, T.B.; Villadsen, S.B.; Gao, S.; Ostenfeld, M.S.; Borre, M.; et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer 2011, 128, 1327-1334. [CrossRef] [PubMed]
44. Liu, L.; Qiu, M.; Tan, G.; Liang, Z.; Qin, Y.; Chen, L.; Chen, H.; Liu, J. miR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3. J. Transl. Med. 2014, 12, 305. [CrossRef] [PubMed]
45. Xie, P.; Xu, F.; Cheng, W.; Gao, J.; Zhang, Z.; Ge, J.; Wei, Z.; Xu, X.; Liu, Y. Infiltration related miRNAs in bladder urothelial carcinoma. J. Huazhong Univ. Sci. Technol. 2012, 32, 576-580. [CrossRef] [PubMed]
46. Song, T.; Xia, W.; Shao, N.; Zhang, X.; Wang, C.; Wu, Y.; Dong, J.; Cai, W.; Li, H. Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac. J. Cancer Prev. 2011, 11, 905-911.
47. Ichimi, T.; Enokida, H.; Okuno, Y.; Kunimoto, R.; Chiyomaru, T.; Kawamoto, K.; Kawahara, K.; Toki, K.; Kawakami, K.; Nishiyama, K.; et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int. J. Cancer 2009, 125, 345-352. [CrossRef] [PubMed]
48. Catto, J.W.; Miah, S.; Owen, H.C.; Bryant, H.; Myers, K.; Dudziec, E.; Larre, S.; Milo, M.; Rehman, I.; Rosario, D.J.; et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009, 69, 8472-8481. [CrossRef] [PubMed]
49. Yoshino, H.; Chiyomaru, T.; Enokida, H.; Kawakami, K.; Tatarano, S.; Nishiyama, K.; Nohata, N.; Seki, N.; Nakagawa, M. The tumour-suppressive function of miR-1 and miR-133a targeting tagln2 in bladder cancer. Br. J. Cancer 2011, 104, 808-818. [CrossRef] [PubMed]
50. Chiyomaru, T.; Enokida, H.; Kawakami, K.; Tatarano, S.; Uchida, Y.; Kawahara, K.; Nishiyama, K.; Seki, N.; Nakagawa, M. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol. Oncol. 2012, 30, 434-443. [CrossRef] [PubMed]
51. Chiyomaru, T.; Enokida, H.; Tatarano, S.; Kawahara, K.; Uchida, Y.; Nishiyama, K.; Fujimura, L.; Kikkawa, N.; Seki, N.; Nakagawa, M. miR-145 and miR-133a function as tumour suppressors and directly regulate fscn1 expression in bladder cancer. Br. J. Cancer 2010, 102, 883-891. [CrossRef] [PubMed]
52. Uchida, Y.; Chiyomaru, T.; Enokida, H.; Kawakami, K.; Tatarano, S.; Kawahara, K.; Nishiyama, K.; Seki, N.; Nakagawa, M. miR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol. Oncol. 2011, 31, 115-123. [CrossRef] [PubMed]
53. Epstein, J.I.; Amin, M.B.; Reuter, V.R.; Mostofi, F.K. The world health organization/international society of urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee. Am. J. Surg. Pathol. 1998, 22, 1435-1448. [CrossRef] [PubMed]
54. Beecken, W.D.; Engl, T.; Hofmann, J.; Jonas, D.; Blaheta, R. Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder. J. Cell. Mol. Med. 2005, 9, 655-661. [CrossRef] [PubMed]
55. Mahmoud, M.A.; Ali, M.H.; Hassoba, H.M.; Elhadidy, G.S. Serum interleukin-8 and insulin like growth factor-1 in egyptian bladder cancer patients. Cancer Biomark. 2010, 6, 105-110. [PubMed]
56. Seguchi, T.; Yokokawa, K.; Sugao, H.; Nakano, E.; Sonoda, T.; Okuyama, A. Interleukin-6 activity in urine and serum in patients with bladder carcinoma. J. Urol. 1992, 148, 791-794. [PubMed]
57. Kovacs, E. Investigation of interleukin-6 (il-6), soluble IL-6 receptor (sIL-6r) and soluble gp130 (sgp130) in sera of cancer patients. Biomed. Pharmacother. 2001, 55, 391-396. [CrossRef]
58. Chen, M.F.; Lin, P.Y.; Wu, C.F.; Chen, W.C.; Wu, C.T. Il-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS ONE 2013, 8, e61901. [CrossRef] [PubMed]
59. Agarwal, A.; Verma, S.; Burra, U.; Murthy, N.S.; Mohanty, N.K.; Saxena, S. Flow cytometric analysis of Th1 and Th2 cytokines in pbmcs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol. Immunother. CII 2006, 55, 734-743. [CrossRef] [PubMed]
60. Salman, T.; el-Ahmady, O.; el-Shafee, M.; Omar, S.; Salman, I. The clinical value of cathepsin-D and TNF-alpha in bladder cancer patients. Anticancer Res. 1997, 17, 3087-3090. [PubMed]
61. Chikazawa, M.; Inoue, K.; Fukata, S.; Karashima, T.; Shuin, T. Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology 2008, 75, 335-345. [CrossRef] [PubMed]
62. Ma, Q. Role of Nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 401-426. [CrossRef] [PubMed]
63. Deshane, J.; Chen, S.; Caballero, S.; Grochot-Przeczek, A.; Was, H.; Li Calzi, S.; Lach, R.; Hock, T.D.; Chen, B.; Hill-Kapturczak, N.; et al. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J. Exp. Med. 2007, 204, 605-618. [CrossRef] [PubMed]
64. Zhu, Z.; Shen, Z.; Xu, C. Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Med. Inflamm. 2012, 2012, 528690. [CrossRef] [PubMed]
65. Yoshino, H.; Enokida, H.; Chiyomaru, T.; Tatarano, S.; Hidaka, H.; Yamasaki, T.; Gotannda, T.; Tachiwada, T.; Nohata, N.; Yamane, T.; et al. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. Biochem. Biophys. Res. Commun. 2012, 417, 588-593. [CrossRef] [PubMed]
66. Wang, T.; Yuan, J.; Feng, N.; Li, Y.; Lin, Z.; Jiang, Z.; Gui, Y. Hsa-miR-1 downregulates long non-coding rna urothelial cancer associated 1 in bladder cancer. Tumour Biol. 2014, 35, 10075-10084. [CrossRef] [PubMed]
67. Wang, H.; Men, C.P. Correlation of increased expression of microRNA-155 in bladder cancer and prognosis. Lab. Med. 2015, 46, 118-122. [CrossRef] [PubMed]
68. Peng, Y.; Dong, W.; Lin, T.X.; Zhong, G.Z.; Liao, B.; Wang, B.; Gu, P.; Huang, L.; Xie, Y.; Lu, F.D.; et al. MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1. Oncotarget 2015, 6, 16043-16058. [CrossRef] [PubMed]
69. Hu, R.; Zhang, Y.; Yang, X.; Yan, J.; Sun, Y.; Chen, Z.; Jiang, H. Isoflurane attenuates LPS-induced acute lung injury by targeting miR-155-HIF1-alpha. Front. Biosci. 2015, 20, 139-156.
70. Bruning, U.; Cerone, L.; Neufeld, Z.; Fitzpatrick, S.F.; Cheong, A.; Scholz, C.C.; Simpson, D.A.; Leonard, M.O.; Tambuwala, M.M.; Cummins, E.P.; et al. Microrna-155 promotes resolution of hypoxia-inducible factor 1α activity during prolonged hypoxia. Mol. Cell. Biol. 2011, 31, 4087-4096. [CrossRef] [PubMed]
71. Zhang, J.; Braun, M.Y. Protoporphyrin treatment modulates susceptibility to experimental autoimmune encephalomyelitis in miR-155-deficient mice. PLoS ONE 2015, 10, e0145237. [CrossRef] [PubMed]
72. Zhang, J.; Vandevenne, P.; Hamdi, H.; Van Puyvelde, M.; Zucchi, A.; Bettonville, M.; Weatherly, K.; Braun, M.Y. Micro-RNA-155-mediated control of heme oxygenase 1 (HO-1) is required for restoring adaptively tolerant cd4+ T-cell function in rodents. Eur. J. Immunol. 2015, 45, 829-842. [CrossRef] [PubMed]
73. Pulkkinen, K.H.; Yla-Herttuala, S.; Levonen, A.L. Heme oxygenase 1 is induced by miR-155 via reduced bach1 translation in endothelial cells. Free Radic. Biol. Med. 2011, 51, 2124-2131. [CrossRef] [PubMed]
74. Stachurska, A.; Ciesla, M.; Kozakowska, M.; Wolffram, S.; Boesch-Saadatmandi, C.; Rimbach, G.; Jozkowicz, A.; Dulak, J.; Loboda, A. Cross-talk between microRNAs, nuclear factor E2-related factor 2, and heme oxygenase-1 in ochratoxin a-induced toxic effects in renal proximal tubular epithelial cells. Mol. Nutr. Food Res. 2013, 57, 504-515. [CrossRef] [PubMed]
75. Gao, C.; Peng, F.H.; Peng, L.K. miR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1. Neoplasma 2014, 61, 680-689. [CrossRef] [PubMed]
76. Tejero, R.; Navarro, A.; Campayo, M.; Vinolas, N.; Marrades, R.M.; Cordeiro, A.; Ruiz-Martinez, M.; Santasusagna, S.; Molins, L.; Ramirez, J.; et al. miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS ONE 2014, 9, e101899. [CrossRef] [PubMed]
77. Chuang, T.D.; Panda, H.; Luo, X.; Chegini, N. miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5. Endocr. Relat. Cancer 2012, 19, 541-556. [CrossRef] [PubMed]
78. Erturk, E.; Cecener, G.; Tezcan, G.; Egeli, U.; Tunca, B.; Gokgoz, S.; Tolunay, S.; Tasdelen, I. Brca mutations cause reduction in miR-200c expression in triple negative breast cancer. Gene 2015, 556, 163-169. [CrossRef] [PubMed]